Harness the Power of Powerdoma™ for Accelerated Antibody
Sequencing and High-throughput Functional Assays
GenScript ProBio is advancing antibody discovery with the cutting-edge Powerdoma™ Hybridoma Discovery Platform. Standing robust amidst evolving technology, hybridoma technology offers unrivaled reliability, success rates, and cost-efficiency for antibody drug lead generation. Our pioneering platform swiftly procures monoclonal cells post-fusion, eliminating traditional subcloning and enabling rapid transition to NGS sequencing and recombinant expression. This process cuts recombinant antibody production time to a mere 1.5 months. Additionally, we empower early-stage cell-based functional assays, improving the signal-to-noise ratio and data reliability. Opt for GenScript ProBio's Powerdoma™ Hybridoma Discovery Platform for speed, precision, and uncompromised quality in antibody discovery.
The Powerdoma™ Hybridoma Discovery Platform facilitates high-throughput detection using diverse techniques such as ELISA, FACS, and cell-based mirrorball assays. Consistent positive results are observed across the board, both from the 384-well high-throughput screening and the conventional 96-well screening.
Figure 1 ELISA 384-well whole plate screening
Figure 2 FACS 384-well VS 96-well
As of March 2023, ProBio boasts an impressive record of over 150 completed therapeutic antibody development projects, leveraging our hybridoma discovery platform. These projects have spanned a diverse range of disease targets, with more than 50 projects specifically targeting transmembrane proteins. On average, each animal utilized in the process delivers over 500 positive binders for further scrutiny and selection.".
Utilizing hybridoma discovery technology, successful screening of mouse antibodies targeting human proteins was achieved in just 116 days, starting from mouse immunization. From a pool of 19,200 hybridoma clones, 87 cross-positive clones were obtained after examining the cross-reactivity of human and cynomolgus proteins. Of these, 79 clones demonstrated strong binding to the overexpressed cell line. 4 optimal clones were selected for sequencing and recombinant expression, ultimately yielding 3 antibodies exhibiting binding activity.
Figure 1 Flowchart of mouse antibody discovery for single-pass membrane target A
Figure 3. ELISA binding of recombinant supernatant
All of the evaluated monoclonal antibodies demonstrated notable cross-species activity, successfully binding with target proteins found in both human and cynomolgus monkey specimens.
Figure 4. FACS binding of recombinant supernatant
All the tested monoclonal antibodies were capable of binding effectively with cell lines expressing the human protein of interest.
Please download service quotation form and fill it before sending to us.